MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Novocure Ltd Company Profile (NASDAQ:NVCR)

Consensus Ratings for Novocure Ltd (NASDAQ:NVCR) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $28.67 (170.19% upside)

Analysts' Ratings History for Novocure Ltd (NASDAQ:NVCR)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016WedbushReiterated RatingOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016JPMorgan Chase & Co.Reiterated RatingOverweight$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetSell$16.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Deutsche BankInitiated CoverageHold -> Hold$28.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2015Evercore ISIInitiated CoverageBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2015JMP SecuritiesInitiated CoverageOutperform$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Novocure Ltd (NASDAQ:NVCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/9/2016        
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Novocure Ltd (NASDAQ:NVCR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.32)($0.31)($0.32)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.43)($0.43)($0.43)
Q4 20161($0.42)($0.42)($0.42)
(Data provided by Zacks Investment Research)
Dividend History for Novocure Ltd (NASDAQ:NVCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Novocure Ltd (NASDAQ:NVCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Novocure Ltd (NASDAQ:NVCR)
DateHeadline
06/23/16 06:04 PMNovocure Ltd (NASDAQ:NVCR) Earnings Glance and Target Price Review - Engelwood Daily
06/19/16 09:29 AMCramer: Media sending you off the scent for this stock - Yahoo7 News
06/17/16 07:00 AMStrength Seen in NovoCure (NVCR): Stock Rises by 5.1% -
06/10/16 05:50 PMNovocure Ltd (NASDAQ:NVCR) announced that the (FDA) has approved its investigational device exemption (IDE ... - Inside Trade
06/10/16 07:07 AMNovocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : June 10, 2016 -
06/08/16 06:18 AMNovocure to Present at JMP Securities 2016 Life Sciences Conference - [at noodls] - Released : 06/08/2016 ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced that Mike Ambrogi, Novocure's Chief Operating Officer, will present at the JMP Securities 2016 Life Sciences ...
06/01/16 06:00 PMNovocure Ltd (NASDAQ:NVCR) Stock Update & Estimates - Stock Tick Tock - Novocure Ltd (NASDAQ:NVCR) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Novocure Ltd (NASDAQ:NVCR) to post earnings of $-0.35 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/01/16 08:29 AMTarget Price and Stock Performance Rundown for Novocure Ltd (NASDAQ:NVCR) - HNN - Target Price and Stock Performance Rundown for Novocure Ltd (NASDAQ:NVCR)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Novocure Ltd (NASDAQ:NVCR) shares ...and more »
05/31/16 05:49 PM3 Biotech Stocks Making Waves - Schaeffers Research (blog) - Schaeffers Research (blog)3 Biotech Stocks Making WavesSchaeffers Research (blog)NVCR received FDA approval to begin a Phase III trial of its radiosurgery cancer treatment. The news had the stock as much as 3.6% higher out of the gate, but the shares have since reversed course, last seen down 0.5% at $11.24. Longer term, Novocure ...and more »
05/31/16 06:42 AMNovocure Receives IDE Approval to Initiate METIS Trial - [at noodls] - Released : 05/31/2016 Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer ST. HELIER, Jersey--(BUSINESS ...
05/29/16 12:00 PMNovocure Limited Ord (NASDAQ:NVCR) Shorted Shares Increased By 6.54% - HNN - Novocure Limited Ord (NASDAQ:NVCR) Shorted Shares Increased By 6.54%HNNThe stock of Novocure Limited Ord (NASDAQ:NVCR) registered an increase of 6.54% in short interest. NVCR's total short interest was 2.45M shares in May as published by FINRA. Its up 6.54% from 2.30M shares, reported previously. With 391,300 shares ...
05/27/16 12:21 PMEarnings Review and Stock Rundown for Novocure Ltd (NASDAQ:NVCR) - Wall Street Hints and News - Earnings Review and Stock Rundown for Novocure Ltd (NASDAQ:NVCR)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Novocure Ltd (NASDAQ:NVCR) to post ...and more »
05/25/16 03:07 PMNOVOCURE LTD Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/24/16 10:45 AMEXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today - Nasdaq - EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel TodayNasdaqNovocure (NVCR) has enrolled the 40th and the last patient in its phase 2 pilot trial testing Tumor Treating Fields plus chemotherapy, dubbed PANOVA, in advanced pancreatic cancer. The final data collection date will be six months after the last ...and more »
05/23/16 10:58 AMNovocure : Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer - The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the PANOVA trial ...
05/23/16 06:46 AMNovocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer - [at noodls] - Released : 05/23/2016 The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone ST. HELIER, Jersey--(BUSINESS ...
05/19/16 04:02 PMNovocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer - [at noodls] - Released : 05/19/2016 Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced ...
05/18/16 09:43 PMETF’s with exposure to Novocure Ltd. : May 19, 2016 -
05/18/16 04:12 PMNovocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients - [at noodls] - Released : 05/18/2016 Median overall survival exceeded 15 months in patients with locally advanced pancreatic cancer treated with TTFields therapy combined with gemcitabine Metastatic pancreatic cancer ...
05/18/16 12:04 PMNOVOCURE LTD Financials -
05/17/16 02:30 PMNovocure Ltd. :NVCR-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 10:57 AMNovocure Limited Ord (NASDAQ:NVCR) Short Interest Decreased By 5.36% - Wall Street Hints and News - Novocure Limited Ord (NASDAQ:NVCR) Short Interest Decreased By 5.36%Wall Street Hints and NewsThe short interest to Novocure Limited Ord's float is 5.38%. The stock decreased 0.57% or $0.07 during the last trading session, hitting $12.2. About 219,615 shares traded hands. Novocure Ltd (NASDAQ:NVCR) has declined 35.22% since October 8, 2015 ...and more »
05/13/16 03:12 PMNOVOCURE LTD Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex -
05/13/16 11:00 AMNovacure To Present Fresh Data Exhibiting Additive Efficacy Of Tumor Treating Fields -
05/13/16 08:58 AMNovocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists’ Annual Meeting 2016 - [at noodls] - Novocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists' Annual Meeting 2016 Released : 05/13/2016 Results ...
05/12/16 10:26 AMWorth Watching Intraday Movers: Direxion Shares Exchange Traded Fund Trust(NYSEARCA:ERX), Novocure Ltd ... - NYSE Journal (press release) - NYSE Journal (press release)Worth Watching Intraday Movers: Direxion Shares Exchange Traded Fund Trust(NYSEARCA:ERX), Novocure Ltd ...NYSE Journal (press release)Novocure Ltd(NASDAQ:NVCR) dropped -1.47% and trading at $12.73 in the last trading session. The last trading range of the stock ranges between $11.60 and $13.73. The company's Market capitalization is $1.11 billion with the total Outstanding Shares of ...
05/12/16 08:17 AMBill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman -
05/12/16 06:21 AMBill Ackman parting ways with Bill Doyle -
05/11/16 06:43 PM[$$] Bill Ackman parts ways with man who introduced him to Valeant - [at Financial Times] - Bill Ackman is parting company with the man who introduced him to his disastrous investment in Valeant Pharmaceuticals. Bill Doyle is leaving Mr Ackman's hedge fund, Pershing Square, after less than two ...
05/11/16 04:48 PMPershing Square Says Doyle Leaving Firm Amid Novocure Demands -
05/11/16 04:07 PMNovocure Enters into Employment Agreement with William Doyle - [at noodls] - Released : 05/11/2016 ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today announced that it has entered ...
05/11/16 10:37 AMPerformance Recap and Target Perspective on Novocure Ltd (NASDAQ:NVCR) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Novocure Ltd (NASDAQ:NVCR)B.O.D.Y ConfidentialIn the latest trading session, shares of Novocure Ltd (NASDAQ:NVCR) moved -0.31%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, company shares ...and more »
05/10/16 10:45 AMPre-Open Stock Movers 05/10: (CCXI) (ALXA) (GPRO) Higher; (NLNK) (SCTY) (MNKD) Lower (more...) - StreetInsider.com - Pre-Open Stock Movers 05/10: (CCXI) (ALXA) (GPRO) Higher; (NLNK) (SCTY) (MNKD) Lower (more...)StreetInsider.comChemoCentryx, Inc. (Nasdaq: CCXI) 78.6% HIGHER; Vifor Pharma, a company of the Galenica Group, and ChemoCentryx, Inc. (Nasdaq: CCXI), a biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, ...
05/10/16 05:31 AMNOVOCURE LTD Files SEC form 10-Q, Quarterly Report -
05/10/16 02:41 AMEdited Transcript of NVCR earnings conference call or presentation 9-May-16 9:00pm GMT -
05/09/16 04:08 PMNOVOCURE LTD Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/09/16 03:18 PMNovoCure reports 1Q loss -
05/09/16 03:18 PMNovocure Reports First Quarter 2016 Financial Results and Provides Company Update - [at noodls] - Released : 05/09/2016 Increasing adoption of Optune with 755 prescriptions received in the first quarter 2016, an increase of 73 percent from the first quarter 2015 and 36 percent from the fourth quarter ...
05/09/16 06:07 AMQ1 2016 Novocure Ltd Earnings Release - After Market Close -
05/07/16 10:14 AMNovocure Limited Ord (NASDAQ:NVCR) Shorted Shares Decreased By 6.07% - B.O.D.Y Confidential - Novocure Limited Ord (NASDAQ:NVCR) Shorted Shares Decreased By 6.07%B.O.D.Y ConfidentialThe short interest to Novocure Limited Ord's float is 5.68%. The stock increased 11.02% or $1.25 on May 6, hitting $12.59. About 373,507 shares traded hands or 44.46% up from the average. Novocure Ltd (NASDAQ:NVCR) has declined 42.77% since ...and more »
05/07/16 10:14 AMEarnings Outlook on Novocure Ltd (NASDAQ:NVCR) - B.O.D.Y Confidential - Earnings Outlook on Novocure Ltd (NASDAQ:NVCR)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Novocure Ltd (NASDAQ:NVCR)'s next earnings release which is expected to be posted on or around 2016-05-09. Sell-side research firms on Wall Street are expecting that the company will post EPS of $-0.3 for the ...and more »
05/06/16 03:10 PMNOVOCURE LTD Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/06/16 06:35 AMNovocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma - [Business Wire] - Novocure™ announced today it will deliver new programs to support the glioblastoma community during Brain Tumor Awareness Month. Last year, Novocure held events to listen to the needs of the GBM community, learn how to better support patients and caregivers, and improve connectivity within the community.
05/05/16 06:41 AMNovocure Delivers New Informational Resource for Glioblastoma Brain Cancer - [at noodls] - Released : 05/05/2016 Website and traveling exhibit to support glioblastoma community ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure™ (NASDAQ: NVCR) announced today the availability of a new online resource ...
05/04/16 06:50 AMBlue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune - [at noodls] - Released : 05/04/2016 More than 112 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: ...
04/29/16 07:37 AMNovocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : April 29, 2016 -
04/28/16 10:28 AMNovocure Ltd (NASDAQ:NVCR) Share Rating Recap - B.O.D.Y Confidential - Novocure Ltd (NASDAQ:NVCR) Share Rating RecapB.O.D.Y ConfidentialShares of Novocure Ltd (NASDAQ:NVCR) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/27/16 10:52 AMShare Performance and Target Price Review Novocure Ltd (NASDAQ:NVCR) - B.O.D.Y Confidential - Share Performance and Target Price Review Novocure Ltd (NASDAQ:NVCR)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Novocure Ltd (NASDAQ:NVCR) ended up with a move of +0.35%. Sell-side analysts have given a consensus target price of $28.67 on company shares. Target price projections may differ greatly from one ...and more »
04/27/16 10:52 AMNovocure Ltd (NASDAQ:NVCR) Analyst Rating Review - The Post - Novocure Ltd (NASDAQ:NVCR) Analyst Rating ReviewThe PostCurrently, there are 3 analysts that have provided ratings for Novocure Ltd (NASDAQ:NVCR). 3 have rated the stock a “Strong Buy”, 0 rate it a “Buy”, 1 are putting a Hold rating on the stock, and 0 are recommending “Sell”. Every recommendation can be ...and more »
04/26/16 10:49 AMNovocure Ltd (NASDAQ:NVCR) Share Rating Recap - The Post - Novocure Ltd (NASDAQ:NVCR) Share Rating RecapThe PostShares of Novocure Ltd (NASDAQ:NVCR) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...
About Novocure Ltd

Novocure Ltd logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVCR
  • CUSIP:
Key Metrics:
  • Previous Close: $10.61
  • 50 Day Moving Average: $11.69
  • 200 Day Moving Average: $15.18
  • P/E Ratio: N/A
  • P/E Growth: -1.83
  • Market Cap: $896.75M
  • Current Quarter EPS Consensus Estimate: $-1.38 EPS
Additional Links:
Novocure Ltd (NASDAQ:NVCR) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha